Zobrazeno 1 - 10
of 37
pro vyhledávání: '"J. Jean Cui"'
Autor:
Alice T. Shaw, J. Jean Cui, Robert C. Doebele, David M. Hyman, Shanna Stopatschinskaja, John K. Lim, Jeff Whitten, Juliet Liu, Evan Rogers, Zhongdong Huang, Wei Deng, Dayong Zhai, Judy Nguyen, D. Ross Camidge, Myung-Ju Ahn, Viola W. Zhu, Jessica J. Lin, Jeeyun Lee, Dong-Wan Kim, Byoung Chul Cho, Sai-Hong Ignatius Ou, Alexander Drilon
all supplementary files
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bfb5414f1930e0247c2f633d7f46df3d
https://doi.org/10.1158/2159-8290.22531802.v1
https://doi.org/10.1158/2159-8290.22531802.v1
Autor:
Byoung Chul Cho, Hye Ryun Kim, J. Jean Cui, Min Hee Hong, Hyo Sup Shim, Seok-Gu Kang, Alexander Drilon, Adam J. Schoenfeld, Sung Sook Lee, Han Na Kang, Seong Gu Heo, Chae Won Park, Hun Mi Choi, You Won Lee, Hyeong-Seok Joo, Seok-Young Kim, Dong Hwi Kim, Mi Ran Yun
Purpose:Although first-line crizotinib treatment leads to clinical benefit in ROS1+ lung cancer, high prevalence of crizotinib-resistant ROS1-G2032R (ROS1G2032R) mutation and progression in the central nervous system (CNS) represents a therapeutic ch
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2bb04a28e7405b3dbb222e697738e45e
https://doi.org/10.1158/1078-0432.c.6529067
https://doi.org/10.1158/1078-0432.c.6529067
Autor:
Byoung Chul Cho, Hye Ryun Kim, J. Jean Cui, Min Hee Hong, Hyo Sup Shim, Seok-Gu Kang, Alexander Drilon, Adam J. Schoenfeld, Sung Sook Lee, Han Na Kang, Seong Gu Heo, Chae Won Park, Hun Mi Choi, You Won Lee, Hyeong-Seok Joo, Seok-Young Kim, Dong Hwi Kim, Mi Ran Yun
Supplementary table 1
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2be66098c51dae65b0cf889710dac01f
https://doi.org/10.1158/1078-0432.22475384.v1
https://doi.org/10.1158/1078-0432.22475384.v1
Autor:
Hye Ryun Kim, Seong Gu Heo, Sung Sook Lee, Seok Young Kim, Min Hee Hong, Mi Ran Yun, Hyo Sup Shim, Han Na Kang, J. Jean Cui, Chae Won Park, Alexander Drilon, Hyeong Seok Joo, Dong Hwi Kim, Adam J. Schoenfeld, You Won Lee, Seok Gu Kang, Byoung Chul Cho, Hun Mi Choi
Publikováno v:
Clin Cancer Res
Purpose: Although first-line crizotinib treatment leads to clinical benefit in ROS1+ lung cancer, high prevalence of crizotinib-resistant ROS1-G2032R (ROS1G2032R) mutation and progression in the central nervous system (CNS) represents a therapeutic c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f8b4fef3514dfb3a6b8c6fcc443792c5
https://europepmc.org/articles/PMC10283448/
https://europepmc.org/articles/PMC10283448/
Autor:
Jeeyun Lee, Byoung Chul Cho, Dayong Zhai, Wei Deng, David M. Hyman, Judy Nguyen, Myung-Ju Ahn, Juliet Liu, Dong Wan Kim, Viola W. Zhu, J. Jean Cui, Jeff Whitten, Alice T. Shaw, Shanna Stopatschinskaja, Robert C. Doebele, Zhongdong Huang, Sai-Hong Ignatius Ou, Jessica J. Lin, Evan Rogers, Alexander Drilon, D. Ross Camidge, John K.C. Lim
Publikováno v:
Cancer Discovery. 8:1227-1236
The use of tyrosine kinase inhibitors (TKI) with activity against ALK, ROS1, or TRKA–C can result in significant clinical benefit in patients with diverse tumors harboring ALK, ROS1, or NTRK1–3 rearrangements; however, resistance invariably devel
Autor:
Siraj M. Ali, Viola W. Zhu, Sai-Hong Ignatius Ou, Alexa B. Schrock, Maria Y. Fernandez-Rocha, J. Jean Cui
Publikováno v:
Lung Cancer. 110:32-34
Patients with anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer (NSCLC) derive significant clinic benefit from treatment with ALK inhibitors. Crizotinib was the first approved tyrosine kinase inhibitor (TKI) for this distinct mol
Publikováno v:
Cancer Research. 80:1958-1958
KRAS is frequently mutated in multiple cancer types. Therapeutic targeting of KRAS has proven challenging until recent success of KRAS-G12C inhibitor AMG510 that demonstrated tumor regression in lung and colon cancer patients with a KRAS-G12C mutatio
Autor:
Vivian Nguyen, Maria Barrera, Wei Deng, Evan Rogers, Xin Zhang, J. Jean Cui, Han Zhang, Dong Lee, Ana Parra, Brion W. Murray, Dayong Zhai, Ung Jane
Publikováno v:
Cancer Research. 80:5226-5226
Anaplastic lymphoma kinase (ALK) gene rearrangements occur in up to 7% of patients with non-small cell lung cancer (NSCLC) with the majority as EML4-ALK fusions. Crizotinib (first generation ALK inhibitor) was the first approved ALK inhibitor for the
Publikováno v:
Cancer Research. 80:1957-1957
Kirsten Rat Sarcoma Viral Oncogene homolog (KRAS) is the most frequently mutated oncogene in a broad spectrum of human cancers, including ~30% of non-small cell lung cancer (NSCLC), ~45% of colorectal cancer (CRC) and ~75% of pancreatic cancer. The M
Autor:
T. Hu, H. Zhuang, Zachary Franklin Zimmerman, Dong Lee, Vivek Subbiah, Armin Graber, Jeffrey P. Whitten, J. Jean Cui, Ung Jane, Y. Lu, Dayong Zhai, Wei Deng, J. Liu, R. Xin, Zhongdong Huang, Han Zhang, Evan Rogers, Xin Zhang, A. Drilon
Publikováno v:
Annals of Oncology. 30:v190-v191
Background Oncogenic activation of the receptor tyrosine kinase (RTK) RET via point mutation or genomic rearrangement has been identified in multiple cancers, including medullary and papillary thyroid cancers, and non-small cell lung cancer (NSCLC).